Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
The antiapoptotic protein Bcl-xL negatively regulates the bone-resorbing activity of osteoclasts in mice
Mitsuyasu Iwasawa, Tsuyoshi Miyazaki, Yuichi Nagase, Toru Akiyama, Yuho Kadono, Masaki Nakamura, Yasushi Oshima, Tetsuro Yasui, Takumi Matsumoto, Takashi Nakamura, Shigeaki Kato, Lothar Hennighausen, Kozo Nakamura, Sakae Tanaka
Mitsuyasu Iwasawa, Tsuyoshi Miyazaki, Yuichi Nagase, Toru Akiyama, Yuho Kadono, Masaki Nakamura, Yasushi Oshima, Tetsuro Yasui, Takumi Matsumoto, Takashi Nakamura, Shigeaki Kato, Lothar Hennighausen, Kozo Nakamura, Sakae Tanaka
View: Text | PDF
Research Article Bone biology

The antiapoptotic protein Bcl-xL negatively regulates the bone-resorbing activity of osteoclasts in mice

  • Text
  • PDF
Abstract

The B cell lymphoma 2 (Bcl-2) family member Bcl-xL has a well-characterized antiapoptotic function in lymphoid cells. However, its functions in other cells — including osteoclasts, which are of hematopoietic origin — and other cellular processes remain unknown. Here we report an unexpected function of Bcl-xL in attenuating the bone-resorbing activity of osteoclasts in mice. To investigate the role of Bcl-xL in osteoclasts, we generated mice with osteoclast-specific conditional deletion of Bcl-x (referred to herein as Bcl-x cKO mice) by mating Bcl-xfl/fl mice with mice in which the gene encoding the Cre recombinase has been knocked into the cathepsin K locus and specifically expressed in mature osteoclasts. Although the Bcl-x cKO mice grew normally with no apparent morphological abnormalities, they developed substantial osteopenia at 1 year of age, which was caused by increased bone resorption. Bcl-x deficiency increased the bone-resorbing activity of osteoclasts despite their high susceptibility to apoptosis, whereas Bcl-xL overexpression produced the opposite effect. In addition, Bcl-x cKO osteoclasts displayed increased c-Src activity, which was linked to increased levels of vitronectin and fibronectin expression. These results suggest that Bcl-xL attenuates osteoclastic bone-resorbing activity through the decreased production of ECM proteins, such as vitronectin and fibronectin, and thus provide evidence for what we believe to be a novel cellular function of Bcl-xL.

Authors

Mitsuyasu Iwasawa, Tsuyoshi Miyazaki, Yuichi Nagase, Toru Akiyama, Yuho Kadono, Masaki Nakamura, Yasushi Oshima, Tetsuro Yasui, Takumi Matsumoto, Takashi Nakamura, Shigeaki Kato, Lothar Hennighausen, Kozo Nakamura, Sakae Tanaka

×

Figure 2

Generation and skeletal analysis of Bcl-x cKO mice.

Options: View larger image (or click on image) Download as PowerPoint
Generation and skeletal analysis of Bcl-x cKO mice.
   
(A) Western blot...
(A) Western blotting of Cre recombinase and Bcl-xL in Bcl-x cKO mice and their normal Bcl-xfl/fl littermates using β-actin as an internal control. Bcl-xL expression was markedly reduced in osteoclasts, but not in osteoblasts, of Bcl-x cKO mice. (B) Histological sections of proximal tibia and lumbar spine of male Bcl-x cKO mice and their normal Bcl-xfl/fl littermates at 8 weeks of age. Bcl-x cKO mice exhibited reduced bone mass. Scale bars: 100 μm. (C) Histomorphometric analysis of male Bcl-x cKO mice and their normal Bcl-xfl/fl littermates at 8 weeks of age. Bone volume per trabecular volume (BV/TV) significantly decreased in Bcl-x cKO mice (P < 0.01). Trabecular bone thickness (Tb.th) and trabecular bone number (Tb.N) was reduced, and the trabecular separation (Tb.S) was increased, in Bcl-x cKO mice, with marginal statistical difference (P < 0.1). As for osteoclast markers, whereas the eroded surface/bone surface (ES/BS) significantly increased in Bcl-x cKO mice (P < 0.05), neither osteoclast number nor osteoclast surface increased. The parameters of bone formation in Bcl-x cKO mice were equivalent to those of normal littermates. Results are mean ± SD of 3 different samples. *P < 0.01 versus normal Bcl-xfl/fl littermates. Oc.N/B.Pm, number of mature osteoclasts per 100-μm bone perimeter; Oc.S/BS, bone surface covered by mature osteoclasts; Osteoid V/BV, osteoid volume per bone volume; Osteoid S/BS; osteoid surface per bone surface; Ob.S/BS, bone surface covered by cuboidal osteoblasts; MAR, mineral apposition rate; BFR, bone formation rate.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts